Irritable Bowel Syndrome (IBS) Treatment Market Share

  • Report ID: 6494
  • Published Date: Oct 01, 2024
  • Report Format: PDF, PPT

Irritable Bowel Syndrome (IBS) Treatment Market Share

North America Market Forecast

North America IBS treatment market is expected to capture a share of 36.4% through 2037 owing to the presence of advanced healthcare facilities and ongoing advancements in the pharma sector. The presence of early adopters in the region is driving the sales of innovative irritable bowel syndrome drugs. The North America irritable bowel syndrome treatment market is estimated to increase from USD 1.5 billion in 2025 to USD 3.9 billion by 2037.

The U.S. IBS treatment market is forecasted to rise at a CAGR of 8.3% and reach USD 3.6 billion by 2037. The strong presence of key market players is fuelling the sales of irritable bowel syndrome drugs in the country. In Canada, the increasing prevalence of irritable bowel syndrome issues is anticipated to boost the market growth during the forecasted period. The Canadian Digestive Health Foundation reveals that the prevalence rate of irritable bowel syndrome is around 18% in the country.

Asia Pacific Market Statistics

Asia Pacific irritable bowel syndrome treatment market is expected to increase at a fast pace during the forecasted period owing to the increasing spending on healthcare infrastructure, expanding pharmaceutical manufacturing companies, and growing cases of obesity leading to IBS issues. India, Japan, South Korea, and China are the most profitable economies for irritable bowel syndrome drug manufacturers.

The high investments in healthcare infrastructure development projects and favorable government policies on drug production are generating profitable opportunities for irritable bowel syndrome therapeutic solution producers in India. The country is emerging as a medical tourism hub owing to the presence of cost-effective and advanced technologies and skilled expertise for various treatments. For instance, the local government is focusing on increasing its Pradhan Mantri Bhartiya Jan Aushadhi Kendras to 10,500 by March 2025. This is set to boost the sales of IBS drugs in the country.

Research Nester
Irritable Bowel Syndrome (IBS) Treatment Market Share
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 6494
  • Published Date: Oct 01, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The global irritable bowel syndrome (IBS) treatment market will be valued at USD 3.9 billion in 2025.

Expanding at a CAGR of 8.8%, the global market is expected to increase from USD 3.6 billion in 2024 to USD 10.7 billion by 2037.

Some leading companies are Ardelyx, Inc., Abbott Laboratories, Bausch Health Companies Inc., Bayer AG, Ironwood Pharmaceuticals, Inc., and Johnson & Johnson.

The tablet segment is estimated to capture a strong 68.2% of the market share through 2037.

North America is expected to hold 36.4% of the global market share through 2037.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample